Regeneron evp Marion McCourt sells $543,504 in stock
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) saw EVP Commercial Marion McCourt sell 566 shares of the company's common stock for a total of $543,504 on November 16, 2026. The sale occurred as Regeneron's stock was trading near its 52-week high of $991.73, following a strong 44% gain over the past six months. The shares were sold under a pre-arranged Rule 10b5-1 trading plan that McCourt adopted on February 17, 2026.
Following the sale, McCourt directly holds 10,305 shares of Regeneron common stock, with an additional 219 shares held indirectly through a 401(k) Plan. Meanwhile, Regeneron reported strong sales of its leading product, Dupixent, which increased by 35% to $6.54 billion in the third quarter of 2026. The company also received FDA approval for Livsayis (cemdisiran) for treating generalized myasthenia gravis, and Truist Securities reiterating a Buy rating with a $982 price target.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written; may contain errors — check the original.